image
Healthcare - Biotechnology - NASDAQ - US
$ 10.25
2.3 %
$ 469 M
Market Cap
-10.79
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CAPR stock under the worst case scenario is HIDDEN Compared to the current market price of 10.2 USD, Capricor Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CAPR stock under the base case scenario is HIDDEN Compared to the current market price of 10.2 USD, Capricor Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CAPR stock under the best case scenario is HIDDEN Compared to the current market price of 10.2 USD, Capricor Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CAPR

image
$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.020252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
22.3 M REVENUE
-11.55%
-42.6 M OPERATING INCOME
-76.78%
-40.5 M NET INCOME
-81.57%
-40 M OPERATING CASH FLOW
-56.25%
-116 M INVESTING CASH FLOW
-2274.45%
153 M FINANCING CASH FLOW
497.23%
0 REVENUE
0.00%
-25 M OPERATING INCOME
-224.54%
-24.4 M NET INCOME
-242.74%
-6.43 M OPERATING CASH FLOW
56.52%
23.9 M INVESTING CASH FLOW
119.36%
50.4 K FINANCING CASH FLOW
-99.94%
Balance Sheet Capricor Therapeutics, Inc.
image
Current Assets 163 M
Cash & Short-Term Investments 152 M
Receivables 10.4 M
Other Current Assets 1.5 M
Non-Current Assets 7.1 M
Long-Term Investments 0
PP&E 6.87 M
Other Non-Current Assets 222 K
88.88 %6.08 %4.03 %Total Assets$170.5m
Current Liabilities 21 M
Accounts Payable 0
Short-Term Debt 835 K
Other Current Liabilities 20.2 M
Non-Current Liabilities 3.99 M
Long-Term Debt 616 K
Other Non-Current Liabilities 3.38 M
3.34 %80.70 %13.49 %Total Liabilities$25.0m
EFFICIENCY
Earnings Waterfall Capricor Therapeutics, Inc.
image
Revenue 22.3 M
Cost Of Revenue 0
Gross Profit 20.8 M
Operating Expenses 63.4 M
Operating Income -42.6 M
Other Expenses -2.1 M
Net Income -40.5 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)22m021m(63m)(43m)2m(40m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-191.13% OPERATING MARGIN
-191.13%
-181.71% NET MARGIN
-181.71%
-27.82% ROE
-27.82%
-23.74% ROA
-23.74%
-28.32% ROIC
-28.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Capricor Therapeutics, Inc.
image
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -40.5 M
Depreciation & Amortization 1.43 M
Capital Expenditures -1.54 M
Stock-Based Compensation 9.77 M
Change in Working Capital 0
Others -12.7 M
Free Cash Flow -41.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Capricor Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CAPR of $31.6 , with forecasts ranging from a low of $15 to a high of $43 .
CAPR Lowest Price Target Wall Street Target
15 USD 46.34%
CAPR Average Price Target Wall Street Target
31.6 USD 208.29%
CAPR Highest Price Target Wall Street Target
43 USD 319.51%
Price
Max Price Target
Min Price Target
Average Price Target
454540403535303025252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Capricor Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
15 M USD 1
9-12 MONTHS
7. News
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients Capricor Therapeutics CAPR on Friday released four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). benzinga.com - 2 weeks ago
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be featured in the session titled “Therapies that Slow Progression” at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Deramiocel, the company's lead cell therapy candidate, for the potential treatment of Becker Muscular Dystrophy (BMD). This designation strengthens Capricor's strategic position as it advances a fully integrated platform targeting the cardiac and skeletal complications of muscular dystrophy and expands the commercial potential of its lead asset. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement I am downgrading Capricor Therapeutics, Inc. stock from Strong Buy to Hold due to FDA Form 483 risks from a Pre-License Inspection of its manufacturing facility. While deramiocel's clinical data for DMD Cardiomyopathy is strong, the unresolved FDA inspection findings create significant regulatory uncertainty for CAPR. The timing of the FDA Advisory Committee meeting and PDUFA date introduces additional risk, as both could be delayed and affect approval prospects. seekingalpha.com - 4 weeks ago
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of the U.S. Food and Drug Administration's (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the Company's lead cell therapy candidate with a Biologics License Application (BLA) under FDA review for potential approval in the treatment of Duchenne Muscular Dystrophy (DMD). The inspection concluded with a Form 483 containing several observations. The Company has submitted its responses to the FDA, none of which required material changes to the cGMP process or facility. The observations were primarily related to routine quality systems and documentation practices. The Company is confident that the facility will meet the necessary requirements to support product licensure and, pending approval, commercial launch. globenewswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 4 weeks ago
8. Profile Summary

Capricor Therapeutics, Inc. CAPR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 469 M
Dividend Yield 0.00%
Description Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Contact 10865 Road to the Cure, San Diego, CA, 92121 https://www.capricor.com
IPO Date Feb. 13, 2007
Employees 160
Officers Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board Ms. Karen G. Krasney Esq., J.D. Executive Vice President, General Counsel & Secretary Dr. Linda Marbán Ph.D. Co-Founder, President, Chief Executive Officer & Director Mr. Anthony J. Bergmann M.B.A. Chief Financial Officer & Corporate Treasurer Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer Mr. Mark Awadalla Chief Development Officer Catherine Lee Kelleher Consultant Mr. Minghao Sun Ph.D. Senior Vice President of Research & Product Development